Lee T. Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair.
TISSUE REPAIR THROUGH THE healing actions of growth factors/ cytokines (trophic factors) is at the forefront of regenerative medicine. Recent stem cell therapeutic studies have led to a realization that the secretion of cytoprotective and tissuerenewing trophic factors by the administered stem cells provides the underlying reparative mechanism independent of stemness (10, 19, 37, 40) . Given that controlled growth factor therapies for heart disease completed so far have not demonstrated convincing clinical efficacy (16, 49) , therapeutic strategies targeting host tissue competence and response can potentially enhance treatment efficacy and reduce unwanted side effects (26) .
Among many tissues in the human body, the heart is feeble in its prowess for regeneration, and heart failure is becoming an increasing medical challenge as life expectancy continues to increase. In contrast, the skeletal muscle is endowed with an impressive ability to regenerate after injury, and this ability is coupled to paracrine production of many trophic factors possessing cardioprotective effects, which has increasingly been recognized (32, 53, 56) . Taking advantage of this capacity of the skeletal muscle, we demonstrated an extracardiac therapeutic regimen based on intramuscular delivery of recombinant VEGF-A 165 for repair of the failing hamster heart (61) . This relatively noninvasive intramuscular VEGF therapeutic strategy stimulates cardiomyogenesis and angiogenesis, attenuates myocardial injury and fibrosis, and improves ventricular function. A salient feature of this distal organ repair mechanism is increased synthesis from the VEGF-injected muscle of major trophic factors such as stromal-derived factor-1 (SDF1 or CXCL12), FGF, hepatocyte growth factor, IGF, NGF, and VEGF (61) . Induction of these muscle-derived trophic factors appears to functionally impact the bone marrow and myocardial compartments as evidenced by robust mobilization of bone marrow progenitor cells and amplification of cardiac progenitor cells, both of which are critically involved in myocardial regeneration (4, 22, 51) . However, the principal trophic mechanisms responsible for these cellular events leading to cardiac repair after intramuscular VEGF remain to be elucidated.
Among the multiple trophic factors induced by intramuscular VEGF (61) , SDF1 is unique in its abilities to mediate the mobilization and trafficking of hematopoietic progenitor cells, endothelial progenitor cells, mesenchymal stem cells, osteoclasts, and neural progenitor cells (6, 31, 55, 57, 58) . Belonging to the C-X-C motif chemokine family, SDF1 is a constitutively expressed and inducible trophic factor that acts through the CXCR4 receptor (24) . Although the potent progenitor cell recruitment mechanism mediated by SDF1 has been explored in preclinical cardiac therapeutic studies (21, 33, 60) , recent clinical trials of cardiac repair based on the use of marrow-mobilizing agents have been disappointing (2) , suggesting that the bone marrow-heart axis acting alone may be incapable of achieving robust cardiac repair. The work presented here delineates the therapeutic mechanism underlying the comprehensive muscle-marrow-heart axis, which invokes multiple functionally synergistic trophic factors for cardiac repair.
METHODS AND MATERIALS

Administration of recombinant VEGF and SDF1 blocking antibody.
Four-month-old TO2 cardiomyopathic hamsters (30) were purchased from Bio Breeders. Animals were injected twice per week, over the 4-wk course of the study, in both the left and right hamstrings with either saline or 1 g/kg of recombinant VEGF. The SDF1 blocking antibody (No. MAB310; R&D Systems) at 500 g/kg body weight was delivered via intraperitoneal injection twice per week for 4 wk. The SDF1 blocking effect of this antibody has been characterized previously (11, 25, 35) . Blood samples were collected via retro-orbital eye bleed or cardiac puncture (for terminal stage only). Tissues were harvested and processed by one of three methods: fixed in freshly prepared 4% paraformaldehyde, embedded in optimal cutting temperature compound, or snap frozen in liquid nitrogen for RNA and protein preparations.
All procedures and protocols conformed to institutional guidelines for the care and use of animals in research and were approved by the University of Buffalo's Institutional Animal Care and Use Committee.
Echocardiography. Echocardiographic measurements were performed with the animals anesthetized to a semiconscious state during the procedure (61) . Animals were anesthetized by intraperitoneal injection of ketamine (30 mg/kg) and xylazine (2 mg/kg). Multiple M-mode images were obtained from the short-axis view of the left ventricle at the level of the papillary muscles with a GE Vingmed echocardiography machine using a 10-MHz transducer. From this image, left ventricular end-systolic dimension and left ventricular end-diastolic dimension were measured in a blinded manner. These dimensions were measured and averaged from at least two consecutive cardiac cycles.
ELISA analysis. Trophic factor concentrations of cell culture media and soluble tissue/cell extracts were measured using ELISA kits. Snap frozen tissues or cells were homogenized in an ice-cold lysis solution (normal saline supplemented with 0.1% TX-100 and 2 mM EDTA). Tissue homogenates were clarified, diluted to 1 mg proteins per milliliter, and stored at Ϫ80°C. SDF1 ELISA was performed using the DuoSet kit (No. DY460) from R&D systems. Circulating cardiac troponin-I was assayed with an ELISA kit (No. 2010-2-HSP) from Life Diagnostics using plasma samples collected one month after intramuscular VEGF.
Flow cytometry analysis of peripheral blood cells. Hamster blood samples were collected either by retro-orbital bleeding or by cardiac puncture when terminating the animals. Anticoagulated blood was separated by centrifugation and plasma was removed and frozen at Ϫ80°C for future analysis while cells were processed for flow cytometry as described (61) . After red blood cell lysis, cells were washed and passed through a BD Falcon 100-cell strainer. Cells were blocked using an FcR receptor blocker (No. 130-059-901; Miltenyi Biotec) for 30 min and labeled with the following antibodies: phycoerythrin (PE) conjugated c-kit (No. 12-1171; eBioscience), PE-conjugated CD31 (No. 12-0311; eBioscience), and PE-conjugated CXCR4 (No. 12-9991; eBioscience) antibodies. Isotype-matched immunoglobulins were used as controls. All antibodies were used at a final concentration of 5 g/ml. Cells were stained for 1 hour on ice and protected from light. Flow cytometry was performed on ϳ50,000 cells using a Becton Dickinson FACS Calibur four-color flow cytometer. Data were analyzed using FCS Express (De Novo Software). Dead cells were excluded through 7-amino-actinomycin D staining.
Bone marrow mesenchymal stem cells and peripheral blood progenitor cells. Bone marrow mesenchymal stem cells (MSC) of 4-mo TO2 hamsters were isolated from femur and amplified through plastic adherence in DMEM/F12 containing 10% FBS as described previously (52) . The hamster MSC were found to exhibit robust osteogenic and chondrogenic differentiation potentials (data not shown). MSC less than five passages were used for RNA analysis. Mobilized bone marrow progenitor cells were isolated from peripheral blood mononuclear cells collected from saline-and VEGF-injected TO2 hamsters and amplified through plastic adherence in the same culture medium. Although progenitor cells from the saline-injected animal failed to grow in culture, those isolated from the VEGF-injected animal were able to form colonies and grow for several passages in culture. These cells were therefore analyzed for expression of trophic factors.
Quantitative PCR. RNA extraction from cultured cells and hamster tissues was performed using Qiagen's RNA isolation kits, and quantitative PCR (qPCR) protocols were as described (28, 61) . In brief, PCR was performed using the MyIQ machine with the SYBR green kit (Bio-Rad). Amplification conditions after an initial denaturation step for 3 min at 95°C were: 45 cycles of 95°C 10 s for denaturation and 55°C 30 s for annealing and elongation. Melting curve analysis was performed to check for a single amplicon. MyIQ analysis software was used for determining crossing points. ␤2-Microglobulin was used as the reference gene for calculations. Data were analyzed by the 2 ⌬⌬CT method. Oligonucleotides were synthesized by Midland Oligo. Primer sequences are listed in Table 1 .
Quantification of capillary and myocyte nuclear densities. Quantification of capillary and cardiomyocyte densities have been documented (61) . In brief, ventricular heart sections were blocked with normal saline supplemented with 0.025% Tween-20 and 2% nonfat milk powder for 45 
Capillary and cardiomyocyte nuclear densities were normalized to total tissue area in squared millimeters.
Morphometric analysis. Morphometric analysis of myocyte size provides a histological indicator of the extent of myocardial regeneration (41, 44) . Hematoxylin-eosin-stained paraffin sections were used to determine cross-sectional cardiomyocyte area using a modified measurement protocol (41) . At least 15 random fields at 200ϫ magnification were assessed for each slide in an operator-blinded fashion. Cross-sectional area was measured manually by tracing along the perimeter of every cardiomyocyte in full view. At least 350 random cardiomyocytes were measured for each animal using the AxioVision LE software measurement tool (Carl Zeiss, Germany).
In situ immunostaining. CXCR4 antibody staining was performed on optimal cutting temperature-embedded heart tissue. Frozen sections were fixed in acetone-ethanol mixture (3:1 ratio) for 5 min and then blocked with normal saline supplemented with 0.025% Tween-20 and 2% nonfat milk. CXCR4 antibody (No. OPA1-01101; Thermo Scientific) was incubated overnight at 4°C and then incubated with Alexa 647 conjugated anti-rabbit secondary antibody for 1 h. Stained sections were further incubated with a myosin heavy chain antibody for 3 h and then incubated with Alexa 488 conjugated anti-goat secondary antibody for 1 h. The sections were mounted using Vectashield Mounting Medium with DAPI (Vector Laboratories). Images were taken in 10 random fields using Zeiss's Axioimager fluorescence microscope at 200ϫ magnification. The number of CXCR4 ϩ cells and the total number of nuclei were counted and the percentage of CXCR4 ϩ cells in the heart was recorded.
Quantification of myocardial apoptosis. Analysis of apoptosis was performed on frozen sections prepared as described above and documented previously (61) using the ApopTag kit (Millipore) per manufacturer's instructions. cTnT antibody was used to identify apoptotic cardiomyocytes, and analysis was performed as described above. All apoptotic nuclei in each section were counted and normalized to total myocytes and nonmyocytes.
Statistical analysis. Statistical analysis was performed using Sigma Stat version 3.0. All results are expressed as means Ϯ SE. Statistical significance was evaluated using the unpaired Student's t-test for comparisons between two means. Statistical significance for multiple groups was evaluated by ANOVA analysis followed by the HolmSidak method for multiple comparisons. Significance was set at P Ͻ 0.05.
RESULTS
Increased SDF1 after intramuscular VEGF recruits myocardial progenitor cells harboring CXCR4.
Although our previous therapeutic study demonstrated the efficacy of intramuscular VEGF in repairing the failing hamster heart (61), the key 1 . Intramuscular VEGF increases circulating and myocardial stromal-derived factor-1 (SDF1). A: hamster plasma and heart tissue protein extracts were analyzed by SDF1 ELISA. Plasma and heart SDF1 were expressed as picograms per milliliter and picograms per milligrams soluble proteins, respectively (n ϭ 4). B: immunostaining of CXCR4 ϩ (pink) cells in the heart. Cardiomyocytes were stained by a troponin-T antibody (green). Nuclei were stained by diamidino-2-phenylindole (DAPI) (blue). Computer quantification of CXCR4 ϩ cells in the heart after intramuscular VEGF is presented below the image (n ϭ 4). C: myocardial CXCR4 gene expression after intramuscular saline or VEGF injections were analyzed by quantitative PCR (qPCR). *P Ͻ 0.05 vs. saline; **P Ͻ 0.01 vs. saline.
trophic mechanism leading to cardiac repair remains to be characterized. Robust mobilization of bone marrow progenitor cells after intramuscular VEGF, however, suggests a prominent role of SDF1 in the therapeutic cascade. Indeed, the ELISA analysis presented in Fig. 1A shows significantly increased circulating SDF1 after intramuscular VEGF, reaching ϳ100 pg/ml from the ϳ40 pg/ml control level. Heart tissue homogenates also exhibited a near doubling of SDF1 concentration (Fig. 1A) after intramuscular VEGF (ϳ600 pg/mg proteins vs. ϳ1,100 pg/mg). Increased circulating and myocardial SDF1 is expected to actively recruit bone marrow progenitor cells harboring CXCR4, which is the C-X-C motif receptor for SDF1. We preformed CXCR4 immunostaining on heart sections, which revealed interstitial cells of ϳ10 m in size harboring perinuclear CXCR4 (Fig. 1B) . Quantification of these troponin-T-negative cells revealed a twofold increase in the myocardial CXCR4 ϩ cells after intramuscular VEGF (Fig.  1B) . Consistent with this finding, qPCR analysis also revealed a twofold increase in myocardial expression of CXCR4 (Fig.  1C) . These results indicate that intramuscular VEGF efficiently activates the SDF1/CXCR4 axis for recruitment of myocardial progenitor cells.
Mobilized bone marrow progenitor cells express cardiac transcription factors and key trophic factors.
The relationship between mobilized bone marrow progenitor cells and cardiac progenitor cells remains incompletely understood. We next used qPCR to better characterize the mobilized bone marrow progenitor cells before their recruitment to the heart. All four surface markers (CD34, CD133, c-kit, and CXCR4) analyzed in Fig. 2A were significantly increased in the peripheral blood mononuclear cells derived from VEGF-injected animals. Notably, these progenitor cells also exhibit a prominent cardiogenic potential as indicated by a significantly elevated expression of the cardiacrestricted transcription factors myocyte enhancer factor 2c and GATA4 (Fig. 2B) . Because stem/progenitor cells are known to produce trophic factors possessing prosurvival and regenerative activities (8, 14) , we analyzed expression of several trophic factors by mobilized progenitor cells in comparison with that of MSC, which exhibit well-known trophic effects on the myocardium (40) . We focused on those trophic factors (FGFs, IGFs, and VEGF) that have been used in clinical trials of cardiac therapy or were found to promote cardiac stem cell function. qPCR analysis of CT presented in Fig. 2C shows that both the mobilized progenitor cells and MSC express readily detectable levels of FGF1, FGF2, IGF1, IGF2, and VEGF. MSC generally express higher levels of the trophic factors with the notable exception of IGF1. The mobilized progenitor cells expressed a 30-fold higher IGF1 than MSC (Fig. 2C) , which is in line with the recent study showing that IGF1 possesses a potent activity in stimulating cardiac progenitor cells (14) . These results indicate that the mobilized progenitor cells possess cardiogenic potential and are capable of activating cardiac stem/progenitor cells through paracrine signaling.
SDF1 blockade abrogates VEGF-mediated mobilization and recruitment of cardiac progenitor cells. To provide functional role of the mobilized progenitor cells in cardiac repair, we performed in vivo SDF1 knockdown by intraperitoneal injections of an SDF1 blocking antibody into the TO2 hamsters, adopting the antibody treatment regimen derived from previous studies (11, 25, 35) . This antibody blockade strategy effectively reduced plasma SDF1 of the VEGF-treated animals to the control level (Fig. 3) . Flow cytometry analysis (Fig. 4) shows significantly increased mobilization after intramuscular VEGF of those progenitor cells displaying the CXCR4, c-kit, and CD31 surface markers as documented previously (61). 
CXCR4
ϩ progenitor cells were most abundant, accounting for ϳ5% of total peripheral blood mononuclear cell, whereas c-kit ϩ and CD31 ϩ progenitor cells represented ϳ0.5% and ϳ0.05% of the mononuclear cells, respectively. The SDF1 blockade abrogated mobilization of these progenitor cells regardless of their abundance (Fig. 4) , demonstrating the absolute role of SDF1 in mobilizing the bone marrow progenitor cells. Interestingly, although VEGF/SDF1 significantly mobilized CD34
ϩ , CD133
ϩ , c-kit ϩ , and CXCR4 ϩ progenitor cells as shown in Fig. 2A , SDF1 blockade only significantly depleted the CXCR4-containing c-kit ϩ progenitor cells in the heart (Fig. 5A) , suggesting that the hematopoietic progenitor lineage (CD34 and CD133) plays a less prominent role in the recruitment of cardiac progenitor cells. Fig. 6 . Regeneration of cardiomyocytes depends on the trophic action of cardiac progenitor cells. Hematoxylin-eosin-stained ventricular heart tissue sections were prepared from the saline group (A), VEGF group (B), and VEGF plus SDF1 blocking antibody group (C) 1 mo after therapy. Representative images from each group were presented. D: cross-sectional myocyte areas were measured for each group, and data were expressed as squared micrometers. E: analysis cross-sectional myocyte area in the TO2 hamster heart from ϳ4 mo of age (pretreatment) to ϳ10 mo of age. *P Ͻ 0.05 comparing A and B; #P Ͻ 0.005 comparing B and C (n ϭ 4 per group). 
CXCR4-expressing c-kit
ϩ progenitor cells provide regenerating trophic factors for the failing heart. Cardiac therapeutic studies have shown that the regenerating heart is supported by increased levels of trophic factors (12, 21, 40, 61) . However, the source of these rejuvenating factors remains elusive. Because SDF1 blockade preferentially impairs the recruitment of CXCR4-expressing c-kit ϩ progenitor cells (Fig. 5A) , it allows us to determine whether the recruited progenitor cells may be a major source of the trophic factors. qPCR analysis (Fig. 5B ) reveals that intramuscular VEGF significantly induced myocardial expression of FGF1, FGF2, IGF1, IGF2, and VEGF, all of which were, however, obliterated with depletion of the c-kit ϩ and CXCR4 ϩ cardiac progenitor cells after SDF1 knockdown. The finding of this cause-effect relationship is highly significant because it suggests that bone marrow-derived CXCR4
ϩ and c-kit ϩ cardiac progenitor cells constitute a major source of trophic factors at least initially for the regeneration of the failing hamster heart.
Regeneration of cardiomyocytes critically depends on progenitor cell-derived trophic factors. Significantly increased cardiomyogenic and angiogenic activities were documented in our previous cardiac therapeutic trials (41, 61) . In particular, we found that the newly formed cardiomyocytes are typically smaller from the studies of the hamster heart failure model as well as the porcine hibernating myocardium model (43, 44) . Many of these smaller myocytes express Ki67 and phosphohistone H3, indicating their mitotic activity. The morphometric analysis was therefore used to assess the role of progenitor cell-derived trophic factors in promoting cardiomyocyte regeneration. Figure 6 shows that the mean cross-sectional myocyte area was smaller in the VEGF-treated group (290 Ϯ 14 m 2 ) than the saline control group (373 Ϯ 25 m 2 ). SDF1 blockade, which abrogated CXCR4 ϩ and c-kit ϩ progenitor cell recruitment and knocked down trophic factor synthesis in the heart, also potently suppressed cardiomyocyte regeneration, as indicated by an increased myocyte size similar to that of the control animal heart (367 Ϯ 35 m 2 ). As a reference, cross-sectional myocyte areas do not change significantly from ϳ4 mo of age (pretreatment) to ϳ10 mo of age in the TO2 hamster heart (Fig.  6E) . Additional morphometric analyses examining capillary and cardiomyocyte densities were performed to confirm this finding. Again, intramuscular VEGF stimulated the capillary and cardiomyocyte nuclear densities, both of which were reduced by SDF1 blockade to the control levels (Fig. 7) . Consonant with the finding on myocyte size, myocyte nuclear density remains constant from ϳ4 mo of age to ϳ10 mo of age in the TO2 hamster heart (Fig. 7D) . Taken together, the SDF1 blocking experiments demonstrate that the cardiac regenerative process is critically driven by mobilization of bone marrow progenitor cells, which are recruited to the heart to enrich the resident cardiac stem cell niche in part through trophic actions.
An SDF1-independent cardioprotective mechanism mediated by the skeletal muscle paracrine cascade. The failing hamster heart exhibits progressive cardiomyocyte loss (30, 41) . Histological analysis with terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling staining to detect Fig. 7 . SDF1 blockade abrogates angiogenesis and cardiomyogenesis mediated by intramuscular VEGF. A: representative images (200ϫ) of capillary and cardiomyocyte staining of heart sections from the saline control, VEGF, and VEGF ϩ SDF1 blocking antibody groups. Cardiomyocytes and capillaries were stained using a troponin-T antibody (red) and FITC-labeled GSL-IB4 lectin (green), respectively. Nuclei were stained by DAPI (blue). B: capillary density per squared millimeters 4 wk after treatments. C: cardiomyocyte nuclear density per squared millimeters 1 mo after treatments. D: analysis myocyte nuclear density in the TO2 hamster heart from ϳ4 mo of age (pretreatment) to ϳ10 mo of age. *P Ͻ 0.05 vs. saline; #P Ͻ 0.05 vs. VEGF (n ϭ 5).
apoptotic cells revealed that intramuscular VEGF reduced apoptotic cardiomyocytes as expected (Fig. 8A) . However, this prosurvival effect of VEGF was only partially inhibited by SDF1 blockade, in contrast with new myocyte formation, which was completely suppressed by SDF1 blockade (Fig. 6) . Consistent with this finding, ELISA analysis of circulating cardiac troponin-I, a marker of myocardial injury, showed that the cardioprotective effect of VEGF was again only partially attenuated by SDF1 blockade (Fig. 8B ). Our previous cardiac therapeutic studies demonstrate that intramuscular VEGF and MSC increase the synthesis by and output from the injected hamstring of several major trophic factors (41, 61) . Because SDF1 blockade abrogated cardiac progenitor cell-derived trophic factors (Fig. 5) , the observed SDF1-independent cardioprotective mechanism could be mediated by the skeletal muscle-derived trophic factors. Indeed, qPCR analysis shows that the synthesis of trophic factors in the injected hamstring was unabated by SDF1 blockade (Fig. 9 ) in sharp contrast with the myocardial trophic factors, which were abrogated by SDF1 blockade (Fig. 5B) .
The results presented above thus uncover two distinct but synergistic cardiac therapeutic mechanisms activated by intramuscular VEGF: 1) SDF1/CXCR4 coordinates the bone marrow and cardiac progenitor cell cascade, contributing to myocardial progenitor cell recruitment and synthesis of trophic factors necessary for cardiomyogenesis and angiogenesis and 2) administration of intramuscular VEGF stimulates the skeletal muscle to produce cardioprotective trophic factors, which upon systemic distribution can directly promote myocardial survival independent of SDF1. Further evidence in support of these dual therapeutic mechanisms is provided by echocardiography, showing that SDF1 blockade only partially attenuated intramuscular VEGF-mediated improvement in left ventricular ejection fraction, left ventricular diastolic diameter, and left ventricular systolic diameter (Fig. 10) . Thus the failing heart of the intramuscular VEGF-treated animal retains moderate function even without the support of the SDF1-dependent progenitor cell cascade.
DISCUSSION
The intramuscular VEGF therapeutic strategy for cardiac repair was born out of our bone marrow MSC research (27, 28, 39 -41) . In particular, we found that human MSC express and secrete fivefold less VEGF than porcine MSC, and this deficiency of human MSC in VEGF output is associated with a reduced cardiac therapeutic efficacy (62) . Overexpression of VEGF in human MSC completely restored their therapeutic efficacy (62) , indicating VEGF as a critical bioactive component of the intramuscular MSC therapy. The current work identified two synergistic cardiac therapeutic mechanisms activated by intramuscular VEGF. As depicted in Fig. 11 , VEGF upon intramuscular delivery activates local expression of trophic factors. Induction of SDF1 serves to mobilize CXCR4-containing c-kit
ϩ , and CD34 ϩ bone marrow progenitor cells, which are recruited to the injured heart for growth factor production and participate in cardiomyogenesis. The SDF1 blockade experiment identifies an SDF1-independent therapeutic mechanism capable of suppressing myocardial apoptotic cell death and tissue injury. This mechanism is likely mediated by the multitude of the skeletal muscle-derived trophic factors capable of activating prosurvival signaling pathways. This dual mechanism of repair of distal organ thus Fig. 9 . SDF1 blockade does not inhibit expression of cardioprotective trophic factors in the VEGF-injected hamstring. qPCR analysis of major trophic factor gene expression in the hamstring 1 mo post-treatments is shown. The 3 animal groups are saline control, VEGF, and VEGF ϩ SDF1 blocking antibody as described above. *P Ͻ 0.05 vs. saline (n ϭ 4). Fig. 8 . Analysis of myocardial apoptosis and injury reveals an SDF1-independent cardioprotective mechanism. A: analysis of cardiomyocyte apoptosis by TUNEL staining. Data were presented as percent TUNEL ϩ nuclei. B: TO2 hamster plasma cardiac troponin-I levels were determined by ELISA after treatments. *P Ͻ 0.05 vs. saline; #P Ͻ 0.05 vs. VEGF (n ϭ 5).
critically hinges on the endocrine function of the skeletal muscle.
Developing efficacious strategies to induce progenitor cell mobilization and recruitment to damaged tissue is at the forefront of regenerative medicine. Although VEGF is well known for its ability to mobilize bone marrow progenitor cells (4), our SDF1 blockade study suggests that this ability of VEGF is orchestrated through SDF1 induction. VEGF and SDF1 are both induced after myocardial infarction (1), and a cross-talk between the two trophic factors has been recognized (20, 47) . Our finding here that the skeletal muscle in response to VEGF exhibits an increased SDF1 output is perhaps not surprising given that the muscle is known to express functional VEGF receptors 1 and 2 (3, 18, 38) . Whether both VEGF receptors may be equally involved in SDF1 induction remains to be determined. Others have reported that VEGF induces SDF1 in perivascular myofibroblasts in association with arterial injury (20) . VEGF induction of SDF1 may be a critical mechanism for tissue repair and regeneration because ongoing VEGF signaling has been found to be essential in maintaining incoming CXCR4 ϩ cells within the target organ (20) . This study also showed that VEGF induces bone marrow cell recruitment and retention in an SDF1-dependent manner. In addition to VEGF, soluble c-kit ligand, thrombopoietin, erythropoietin, and granulocyte-macrophage colony-stimulating factor can induce SDF1 release from platelets (23) . However, subsequent efficient recruitment and engraftment of the mobilized progenitor cells has been found to critically depend on tissue injury-mediated upregulation of cell adhesion molecules (1).
Our flow cytometry and qPCR analyses of peripheral blood mononuclear cells indicate that multilineage progenitor cells are mobilized by intramuscular VEGF, and these cells harbor the hematopoietic stem cell markers CD133 and CD34 in addition to c-kit and CXCR4. A subpopulation of these CXCR4-containing cells appears to possess cardiogenic potential as indicated by prominent expression of the cardiac transcription factors myocyte enhancer factor 2c and GATA4 and thus may function as cardiac stem/progenitor cells upon myocardial recruitment. These cells also express readily detectable levels of several trophic factors, most notably IGF1, indicating that they are capable of paracrine action on the myocardium as observed for MSC (40) . Given that adult cardiac stem cells are normally quiescent but can be activated by trophic factors such as IGF1 (14, 29, 50) , the identified CXCR4-expressing c-kit Three major tissues illustrated are the skeletal muscle, bone marrow, and the diseased heart. The intramuscular injected VEGF activates local expression of trophic factors such as SDF1, FGF, hepatocyte growth factor, IGF, and VEGF as documented previously (61) . The 2 dashed lines indicate the 2 major therapeutic mechanisms activated by intramuscular VEGF: 1) SDF1 serves to mobilize CXCR4-expressing c-kit ϩ , CD133 ϩ , and CD34 ϩ bone marrow progenitor cells. The CXCR4-containing c-kit ϩ progenitor cells are preferentially recruited to the injured myocardium for growth factor production necessary for angiogenesis and cardiomyogenesis; and 2) skeletal muscle-derived paracrine factors serve to attenuate myocardial apoptosis and promote cell survival, and this pathway is independent of SDF1.
identified IGF1 receptor as a key cardiac stem cell axis mediating myocardial regeneration. Thus intracoronary administration of IGF1 robustly promotes regeneration of the infarcted pig heart (14) . Aside from IGF1, the SDF1-mobilized progenitor cells also express abundant VEGF, which is known to stimulate endothelial progenitor cells (17) and promote cardiac stem cell migration (46) . FGF2 has also been shown to stimulate cardiac stem cells for myocardial regeneration (45, 59) . These results highlight the intricate growth factor cross-talk mechanisms mediating stem/progenitor cell function.
Further mechanistic insight is revealed from our SDF1 blocking antibody study. Cardiac c-kit ϩ progenitor cells have been shown to originate from the bone marrow (15) and possess the highest growth and differentiation potential compared with the MDR1 ϩ and Sca-1 ϩ progenitor cells (5, 7). SDF1 blockade in the current study only significantly depleted CXCR4-expressing c-kit ϩ progenitor cells in the heart with a negligible effect on CD133 ϩ and CD34 ϩ progenitor cells, suggesting that the hematopoietic progenitor lineage may play a minor role in the recruitment of cardiac progenitor cells after intramuscular VEGF. Importantly, depletion of the c-kit ϩ and CXCR4 ϩ progenitor cells in the heart completely abolished myocardial trophic factor expression, thus reiterating the functionally important trophic actions mediated by the recruited progenitor cells. Alternatively, it is possible that the progenitor cell-derived trophic factors can further activate resident cardiac stem cells and/or cardiomyocytes to produce growth factors. It is also possible that SDF1 may have a direct effect on myocardial expression of these growth factors. Our in situ immunostaining and qPCR studies indicate that the mobilized CXCR4-expressing c-kit ϩ progenitor cells can populate the injured heart and directly contribute to cardiomyogenesis and angiogenesis. Other studies have demonstrated that CXCR4 ϩ progenitor cells play a central role in myocardial repair (33) , and impaired CXCR4 signaling is associated with a reduced therapeutic effect of endothelial progenitor cells (54) . Engineering of CXCR4-overexpressing stem cells can enhance stem cell therapy for myocardial infarction (48) , and IGF1-overexpressing MSC induce cardiomyogenesis in the infarcted heart by progenitor cell mobilization via SDF1 signaling (21) . Adding to these findings is our demonstration of the VEGF/ SDF1-mediated bone marrow-cardiac progenitor cell axis and the essential role of its trophic actions in amplifying the cardiac stem cell niche.
SDF1 also plays a role in the cell mobilizing actions mediated by G-CSF and cyclophosphamide (34, 36) . Despite the above demonstration of the pivotal role of bone marrow progenitor cell mobilization in cardiac repair, clinical trials of cardiac repair based solely on the use of marrow-mobilizing agents have been disappointing (2) . This may be in part due to the fact that patients with coronary artery disease can exhibit dysfunctional CXCR4 function (54) . In addition, bone marrow support of the heart in pressure overload is lost with aging (42) , suggesting that the SDF1/CXCR4 axis may be perturbed by age-related tissue remodeling. These findings underscore the importance of adopting a synergistic therapeutic strategy for tissue regeneration. Along this line, the current work demonstrates that the VEGF-injected skeletal muscle also benefits the failing heart by providing cardioprotective trophic factors independent of SDF1. The ability of the skeletal muscle to induce trophic factors in response to humoral cues may be particularly important given that it is the largest organ of the body. This property of the muscle has increasingly been recognized and has led to the term "myokines" to describe muscle-derived paracrine factors, many of which act by activating the prosurvival AKT-and ERK-mediated signaling transduction pathways (32, 53) . This prosurvival paracrine mechanism may be particularly important in salvaging the failing heart, which exhibits ongoing cell death and tissue damage. Preconditioning by exercise, for instance, induces VEGF release from the working muscle, which results in decreased infarct size and improved angiogenesis (56) . Our intramuscular VEGF therapeutic study lends support to this finding and provides mechanistic insight regarding the wholebody benefits of exercise. Along this line, we also demonstrated that the skeletal muscle in responding to IL-6-type cytokines derived from MSC initiates a similar paracrine cascade, resulting in increased circulating levels of regenerating factors, and blocking this muscle paracrine cascade abrogates the therapeutic effect of MSC (40) . These findings together demonstrate the impressive and dynamic endocrine function of skeletal muscle under normal and pathophysiologic states.
In summary, this relatively noninvasive extracardiac VEGF therapeutic regimen differs notably from the traditional intracoronary and intramyocardial injection routes, which suffer from impracticability for repeated protein injections necessary for achieving robust muscle activation. In addition to the study of the TO2 hamster heart failure model, we have found that intramuscular delivery of VEGF for the treatment of the porcine hibernating myocardium achieved a significant cardiac therapeutic effect (9) . We propose that the intramuscular VEGF regimen enables the injected skeletal muscle to activate the SDF1-dependent progenitor cell cascade necessary for cardiomyogenesis and amplify the SDF1-independent muscle paracrine cascade capable of direct cardioprotection.
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